**AME Case Series Checklist –Adapted from CARE Checklist and PROCESS Checklist**

| Section          | Item | Checklist description                                                                                                                                                                                                 | Reported on Page Number/Line Number | Reported on Section/Paragraph |
|------------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------|
| Title            | 1    | The diagnosis or intervention of primary focus followed by the words “case series”.                                                                                                                                       | Page 1 / Line 1                     | Title page                     |
| Key Words        | 2    | 2 to 5 key words that identify diagnoses or interventions in this case series, including "case report" or "case series".                                                                                                    | Page 3 / Line 48                    | Abstract                        |
| Abstract         | 3a   | Introduction—What is unique about this case series and what does it add to the scientific literature?                                                                                                                    | Page 2 / Lines 26-28                | Abstract / Background           |
|                  | 3b   | Methods—describe what was done, how and when was it done and by whom.                                                                                                                                                  | Page 2 / Lines 30-35                | Abstract / Methods              |
|                  | 3c   | Results—what was found.                                                                                                                                                                                                 | Page 2 / Lines 37-42                | Abstract / Results              |
|                  | 3d   | Conclusion—What is the main take-away lesson(s)? What have we learned and what does it mean?                                                                                                                           | Page 3 / Lines 44-46                | Abstract / Conclusions          |
| Introduction     | 4    | Explain the scientific background and rationale for the case series.                                                                                                                                                   | Page 4 / Lines 60 - 80              | Introduction                    |
| Methods          | 5a   | Registration and ethics—                                                                                                                                                                                                 | Page 5 / Lines 86 - 88              | Material and Methods / Design and setting |
|                  | 5a.1 | State the research registry number in accordance with the declaration of Helsinki - “Every research study involving human subjects must be registered in a publicly accessible database” (this can be obtained from: ResearchRegistry.com or ClinicalTrials.gov or ISRCTN). |                                      |                                |
|                  | 5a.2 | State whether ethical approval was passed.                                                                                                                                                                             |                                      |                                |
|                  | 5a.3 | Provide the patient consent form too.                                                                                                                                                                                   |                                      |                                |
|                  | 5b   | Study design—state the study is a case series and whether prospective or retrospective in design, whether single or multi-center and whether cases are consecutive or non-consecutive.                                           | Page 5 / Line 84                    | Material and Methods / Design and setting |
|                  | 5c   | Setting - describe the setting(s)and nature of the institution in which the patient was managed; academic, community or private practice setting? Location(s), and relevant dates, including periods of recruitment, exposure, follow-up, and data collection. | Page 5 / Line 85 - 87              | Material and Methods / Design and setting |
|                  | 5d   | Participants—                                                                                                                                                                                                       | Page 5 / Lines 91 - 95              | Material and Methods / Participants |
|                  | 5d.1 | Describe the relevant characteristics of the participants (history, comorbidities, tumor staging, smoking, etc.).                                                                                                                                                       |                                      |                                |
|                  | 5d.2 | State any eligibility (inclusion/exclusion) criteria and the sources and methods of selection of participants.                                                                                                                                                         |                                      |                                |
| Section | Description | Page/Line | Notes |
|---------|-------------|-----------|-------|
| 5e | Intervention—types of intervention (such as pharmacologic, surgical, preventive, self-care) deployed and reasoning behind treatment offered. Pharmacological therapies should include formulation, dosage, strength, route and duration. | 5-6 / Lines 98-105 | Material and Methods / Surgical Technique |
| 5f | Follow up—describe length and methods of follow-up. | 6 / Lines 117-119 | Material and Methods / Surgical Technique |
| Results | Participants—reports numbers involved and their characteristics (comorbidities, tumor staging, smoking, etc.). | 9 / Lines 146-150 | Results |
| 6a | Any changes in the interventions during the course of the case series (how has it evolved, been tinkered with, what learning occurred, etc.) together with rationale and a diagram if appropriate. | N/A, no changes in the intervention | N/A, no changes in the intervention |
| 6b | Outcomes and follow-up—Clinician assessed and patient-reported outcomes (when appropriate) should be stated with inclusion of the time periods at which assessed. Relevant photographs/radiological images should be provided. e.g. 12-month follow-up. | 8 / Lines 151 - 172 | Results |
| 6c | Where relevant—intervention adherence/compliance and tolerability (how was this assessed). Describe loss to follow-up (express as a percentage) and any explanations for it. | 8-9 / Lines 145-146 | Results |
| 6d | Complications and adverse or unanticipated events. | 8 / Lines 158 - 159 | Results |
| Discussion | Summarize key results. | 10 / Lines 188 - 197 | Discussion |
| 7a | Discussion of the relevant literature, implications for clinical practice guidelines. How do outcomes compare with established therapies and the prevailing gold standard? Generate a hypothesis if possible. | 10-11 / Lines 198 - 215 | Discussion |
| 7b | Strengths and limitations of the study. | 11 / Lines 216 - 230 | Discussion |
| 7c | The rationale for any conclusions. | 11-12 / Lines 231 - | Discussion |
| Conclusion | State the key conclusions from the study. | 12 / Lines 240 - 242 | Conclusion |
| 8a | State what needs to be done next, further research with what study design. | 12 / Lines 241-242 | Conclusion |

Article information: http://dx.doi.org/10.21037/jtd-20-3396
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.